At the beginning of the week, our Under the Radar Moversnewsletter suggested small cap development-stage biotech stock Heat Biologics Inc (NASDAQ: HTBX) as a long trade:
To really appreciate the potential upside of Heat Biologics, we have to take a step back and look at it from a distance. As you can see, while the July/August surge spent the next two months cooling off, the technical support it was given during that time was uncanny. In the meantime, it’s firmed up. We’ve developed several bullish moving average crossovers, and we’ve also started to see HTBX find support at its shorter-term moving average lines. The uptrend has been rekindled, even if it’s a shallow ascension so far.
Our Under the Radar Moversnewsletter talks more in-depth about Heat Biologicss technical chart along with a potential long trading strategy:
Top Biotech Stocks To Invest In 2018: Global Eagle Entertainment Inc.(ENT)
- [By Lisa Levin]
Shares of Global Eagle Entertainment Inc (NASDAQ: ENT) were down around 31 percent to $4.30. Global Eagle named Jeff Leddy as Chief Executive Officer. Dave Davis resigned as CEO effective February 20, 2017.
- [By Paul Ausick]
Global Eagle Entertainment Inc. (NASDAQ: ENT) dropped about 1.4% Tuesday, to post a new 52-week low of $14.29 after closing at $14.49 on Friday. The stock’s 52-week high is $19.92. Volume was about 7 times the daily average of around 420,000 shares. The company’s CEO and CFO both resigned unexpectedly this morning.
Top Biotech Stocks To Invest In 2018: MGM Resorts International(MGM)
- [By Ben Levisohn]
MGM Resorts International (MGM) always had two things going for it: It’s large Las Vegas footprint to counter the weakness in Macau, and it’s real-estate, which it spun off into MGM Growth Properties (MGP). But when MGM reported weaker than expected earnings this morning, it wasn’t a good sign that Las Vegas was disappointing. Wells Fargo’sCameron McKnight explains:
Q4 Las Vegas EBITDA of $365mm was 10% ($40MM) below the Street. Las Vegas 4Q RevPAR growth of +3% was in-line with guidance, but below our expectations and industry data. For the 1Q17, MGM provided RevPAR guidance of 7%, a point or two below our expectations. We estimate revenue growth per visitor was +1.5% yr/yr. RevPOR (other revenue per occupied room) growth was +1.5%. We estimate expenses were +1% yr/yr. We expect the stock to be trade down on this morning’s release. While forward guidance was tepid, MGM missed Las Vegas expectations.
Shares of MGM Resorts International have tumbled 7.3% to $27.45 at 11:37 a.m. today, while MGM Resorts Properties has declined 0.3% to $25.58.
- [By JJ Kinahan]
The earnings parade continues as the Fed wraps up its July meeting. Biotech giant Gilead Sciences, Inc. (NASDAQ: GILD) reports today after market close, and tomorrow morning both Verizon Communications Inc. (NYSE: VZ) and MGM Resorts International (NYSE: MGM) release their second-quarter results.
- [By Rich Duprey]
The big casinos certainly want to spend big. Las Vegas Sands (NYSE:LVS) says a new integrated resort in Japan will cost anywhere from $6 billion to $10 billion, two to three times more than it spent on building its brand new French-themed Parisian resort in Macau. MGM Resorts (NYSE:MGM) says it, too, could spend $10 billion for a new casino in Japan, quadruple the cost of its MGM Cotai that’s scheduled to open later this year. Wynn Resorts (NASDAQ:WYNN) hasn’t put a price tag on it yet, though it spent over $4 billion to open the Palace in Macau last August, but CEO Steve Wynn says the opportunity is “thoroughly delicious.”
- [By Ben Levisohn]
Wynn wasn’t the only Macau casino operator that took it on the chin today. Las Vegas Sands (LVS) tumbled 13% to $54.67, while Melco Crown Entertainment (MPEL) plunged 14% to $16.87, and MGM Resorts International (MGM) dropped 4.3% to $28.65.
Top Biotech Stocks To Invest In 2018: Nustar Energy L.P.(NS)
- [By Roberto Pedone]
One technology player that insiders are active in here is Jive Software (NS), which provides a social business software platform to businesses, government agencies, and other enterprises. Insiders are buying this stock into massive weakness, since shares are down sharply by 43% so far in 2014.
Jive Software has a market cap of $446 million and an enterprise value of $365 million. This stock trades at a fair valuation, with a price-to-sales of 2.68 and a price-to-book of 5.67. Its estimated growth rate for this year is 45.5%, and for next year it’s pegged at 30%. This is a cash-rich company, since the total cash position on its balance sheet is $98.18 million and its total debt is $6.60 million.
A director just bought 260,819 shares, or about $1.71 million worth of stock, at $6.53 to $6.60 per share.
From a technical perspective, JIVE is currently trending just above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently pulled back off its short-term high of $7.14 a share with heavy downside volume flows. That drop has now pushed the stock to right above its 50-day moving average at $6.10 a share.
If you’re bullish on JIVE, then I would look for long-biased trades as long as this stock is trending above its 50-day at $6.10 a share and then once it breaks out above some key near-term overhead resistance levels at $7.14 a share to its 200-day moving average of $7.43 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 557,678 shares. If that breakout triggers soon, then JIVE will set up to re-test or possibly take out its next major overhead resistance levels $8.50 to $9 a share, or even $9.50 to $10 a share.
Must Read: 10 Stocks George Soros Is Buying